FDA Determines Regulatory Review Period for INVEGA SUSTENNA Patent Extension

Summary

The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for the patent extension of INVEGA SUSTENNA, a human drug product, in accordance with federal regulations.